Advertisement

Topics

Oncogenic BRAF in cancer - Biotech, Pharma and Life Science Channel

06:27 EST 20th February 2017 | BioPortfolio

Oncogenic BRAF can result from mutations in the BRAF gene, which may cause the protein to become overactive. The most common alteration in the BRAF gene leads to the BRAFV600E mutation. Mutations in the BRAF gene allow for BRAF to signal independently of upstream cues, and result in overactive downstream signaling via MEK and ERK. This, in turn, leads to excessive cell proliferation and survival, independent of growth factors.

Source: http://www.biooncology.com/research-education/braf/targeting

PubMed Articles [200 Associated PubMed Articles listed on BioPortfolio]

Painful nipple hyperkeratosis secondary to vemurafenib.

Vemurafenib is a selected BRAF kinase inhibitor approved for treating metastatic or unresectable melanoma, which has numerous cutaneous side effects unfortunately, including three previously reported ...

PLCB4 copy gain and PLCß4 overexpression in primary gastrointestinal stromal tumors: Integrative characterization of a lipid-catabolizing enzyme associated with worse disease-free survival.

To explore the implications of lipid catabolism-associated genes in gastrointestinal stromal tumors, we reappraised transcriptomic and genomic datasets and identified copy-gained and differentially up...

Melanocyte transformation requires complete loss of all pocket protein function via a mechanism that mitigates the need for MAPK pathway activation.

Deregulation of p16INK4A is a critical event in melanoma susceptibility and progression. It is generally assumed that the major effect of loss of p16 function is mediated through the CDK-cyclin pathwa...

Treatment Options for EGFR T790M-Negative EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer.

The introduction of first- and second-generation EGFR-tyrosine kinase inhibitors (TKIs) (gefitinib, erlotinib and afatinib) for the treatment of advanced EGFR-mutant non-small cell lung cancer (NSCLC)...

Correlations of IGF-1R and COX-2 Expressions with Ras and BRAF Genetic Mutations, Clinicopathological Features and Prognosis of Colorectal Cancer Patients.

This case-control study aims to investigate the correlations of insulin-like growth factor receptor 1 (IGF-1R) and cyclooxygenase 2 (COX-2) expressions with Ras and BRAF genetic mutations, clinicopath...

Time-resolved phosphoproteome analysis of paradoxical RAF activation reveals novel targets of ERK.

Small molecules targeting aberrant RAF activity, like Vemurafenib (PLX4032), are highly effective against cancers harboring the V600E BRAF mutation, and are now approved for clinical use against metas...

PD-L1 up-regulation in melanoma increases disease aggressiveness and is mediated through miR-17-5p.

PD-L1 is expressed by a subset of patients with metastatic melanoma (MM) with an unfavorable outcome. Its expression is increased in cells resistant to BRAF or MEK inhibitors (BRAFi or MEKi). However,...

Presence of cancer-associated mutations in exhaled breath condensates of healthy individuals by next generation sequencing.

Exhaled breath condensate (EBC) is a non-invasive source that can be used for studying different genetic alterations occurring in lung tissue. However, the low yield of DNA available from EBC has hamp...

Heat Shock protein 27 (HSP27, HSPB1) is synthetic lethal to cells with oncogenic activation of MET, EGFR and BRAF.

The small Heat Shock Protein of 27 KDa (HSP27) is highly expressed in many cancers and is associated with aggressive tumor behaviour, metastasis, poor prognosis and resistance to chemotherapy. We aime...

KRAS and PIK3CA mutations in colorectal adenocarcinomas correlate with aggressive histological features and behavior.

Tumor budding (TB) in colorectal carcinoma (CRC) is related to epithelial-mesenchymal transition (EMT) and has been recently characterized as an indicator of poor prognosis along with lymphovascular t...

News Articles [76 Associated News Articles listed on BioPortfolio]

Doctors Treat Deadly Cancerous Disorders with Gene-Guided, Targeted Therapy

CINCINNATI, Feb. 16, 2017 /PRNewswire-USNewswire/ -- Genomic testing of biopsies from patients with deadly, treatment-resistant cancerous blood syndromes called histiocytoses allowed doctors to i...

Array BioPharma Reports Financial Results For The Second Quarter Of Fiscal 2017

BOULDER, Colo., Feb. 9, 2017 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY), a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule can...

Biodesix's GeneStrat liquid biopsy testing now includes ROS1 and RET mutations

Molecular diagnostics firm Biodesix announced that the GeneStrat test, a liquid biopsy for patients with cancer, now includes ROS1 and RET in addition to EGFR sensitizing; EGFR resistance (T790M), KRA...

[Comment] Adjuvant ipilimumab for stage III melanoma: the patient voice

The therapeutic landscape for the management of patients with resected high-risk malignant melanoma is evolving rapidly; however, it remains an important clinical challenge. Adjuvant interferon has si...

GeneStrat Liquid Biopsy Testing™ Now Includes ROS1 and RET Mutations

Actionable mutation results from a single blood draw, 72-hour turnaround time Biodesix®, Inc. announced today that the GeneStrat® test, a liquid biopsy for patients w...

Biodesix GeneStrat Liquid Biopsy Testing™ Now Includes ROS1 and RET Mutations

BOULDER, Colo.--(BUSINESS WIRE)--Biodesix®, Inc. announced today that the GeneStrat® test, a liquid biopsy for patients with cancer, now includes ROS1 and RET in addition to EGFR sensitizing; EG...

2016-Year in Review: Top Advances in Management of Melanoma

2016 was a year of continued advances in the management of melanoma as a result of advances in precision medicine and immunotherapy. Trial results matured defining the role of BRAF inhibitors and comb...

Do High-Fat Diets Fuel BRAF V600E Mutation-Harboring Melanomas?

Dietary fat intake might promote the growth of melanoma tumors harboring BRAF V600E mutations, and lipid-lowering drugs can slow that growth, according to a mouse study.

Addition of Vemurafenib to Irinotecan/Cetuximab Delayed Progression in BRAF-Mutated mCRC

The addition of the BRAF inhibitor vemurafenib to irinotecan and cetuximab prolonged progression-free survival and resulted in a higher disease control rate than treatment with irinotecan and cetuxima...

Vemurafenib Delayed Progression in Metastatic, BRAF-Mutant CRC

This video covers results of the SWOG 1406 study, which tested the BRAF inhibitor vemurafenib in combination with irinotecan and cetuximab for patients with metastatic, BRAF-mutant colorectal cancer.

Events [0 Results]

None

Companies [1 Associated Companies listed on BioPortfolio]

NewGene Limited

The demand for testing individuals for genetic disorders or cancers that have arisen from acquired genetic variations is growing year on year.  This is being driven by advances in medical genet...

Clinical Trials [86 Associated Clinical Trials listed on BioPortfolio]

IV Ascorbic Acid in Advanced Gastric Cancer

Linus Pauling and Dr Ewan Cameron have published two retrospective studies about using high dose vitamin C to treat cancer patients forty years ago. Their studies have shown that high dose...

ML29255 Neoadjuvant Vemurafenib and Cobimetinib Melanoma

Neoadjuvant Vemurafenib and Cobimetinib in BRAF V600 Mutant Stage IIIB-C Melanoma • To evaluate the overall radiological complete response rate in patients with stage IIIB/C melanoma af...

Induction Therapy With Panitumumab + mFOLFOX-6 in Rectal Cancer and Quadruple Wild-type Mutation Before Surgery

Patients with rectal adenocarcinoma of intermediate risk (defined by magnetic resonance imaging [MRI]), without mutations in KRAS, BRAF, NRAS and PI3KCA, who are candidates for preoperativ...

Concurrent Dabrafenib and Trametinib With Sterotactic Radiation in Patients With BRAF Mutation-Positive Malignant Melanoma and Brain Metastases

Dabrafenib and trametinib are drugs that are usually given for the treatment of melanoma. Combinations of dabrafenib and trametinib have also been studied and when used together have shown...

IV Ascorbic Acid in Advanced Colorectal Cancer

Preclinical study has shown that human colorectal cancer cells harboring KRAS or BRAF mutations are selectively killed by high levels of ascorbic acid (AA). High dose of AA impairs tumor g...

A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma

To evaluate the safety and efficacy of the combination of an anti-PD-1 antibody (PDR001), a BRAF inhibitor (dabrafenib) and a MEK inhibitor (trametinib) in unresectable or metastatic BRAF ...

Induction Therapy With Vemurafenib and Cobimetinib to Optimize Nivolumab and Ipilimumab Therapy

Rationale: The combination of ipilimumab and nivolumab induces relatively high response rates and promising response depth in late stage melanoma. Nevertheless, it takes time till respons...

Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib in Patients With BRAF or NRAS-mutated Metastatic Melanoma

The goal of this clinical research study is to learn if nivolumab and trametinib (with or without dabrafenib) can help to control metastatic melanoma in patients who have a BRAF, NRAS, or ...

Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer

The purpose of this study is to determine whether combination therapy of irinotecan with AZD1775 is safe and effective in treating mutated metastatic colorectal cancer patients.

Study of I Line FOLFOX + Panitumumab vs 5FU + Panitumumab in RAS and BRAF WT Metastatic Colorectal Cancer Elderly Patients

- Few data are available about the treatment of metastatic colorectal cancer (mCRC) elderly patients with anti-EGFR agents in combination with chemotherapy. Up today, most of th...

Videos

None available.

Medical and Biotech [MESH] Definitions

None available.

Quick Search
Advertisement
 

Relevant Topics

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

review and buy Oncogenic BRAF in cancer market research data and corporate reports here

Channels Quicklinks